Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.32 USD | -2.58% | -6.21% | -47.40% |
Apr. 15 | RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating | MT |
Apr. 11 | Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating | MT |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.68 for the current period. Therefore, the company is undervalued.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-47.40% | 426M | C+ | ||
-2.31% | 185B | C+ | ||
-3.20% | 105B | C | ||
-5.04% | 66.59B | A | ||
+0.20% | 54.66B | B- | ||
+17.29% | 47.78B | B- | ||
+4.06% | 41.26B | B+ | ||
+2.36% | 26.95B | A- | ||
+2.07% | 26.37B | B | ||
+12.96% | 24.8B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.